Medistep Healthcare (NSE:MEDISTEP) Research & Development: ₹0.0 Mil (TTM As of Mar. 2025)


NSE:MEDISTEP Medistep Healthcare Ltd NSE:MEDISTEP
19 GF Score
Price ₹19.90
! 2 Warning Signs
View Full Analysis

What is Medistep Healthcare Research & Development?

Medistep Healthcare NSE:MEDISTEP 19 Research & Development is ₹0.0 Mil as of Mar. 2025. GuruFocus rates NSE:MEDISTEP with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medistep Healthcare's Research & Development for the six months ended in Mar. 2025 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was ₹0.0 Mil.

Medistep Healthcare  (NSE:MEDISTEP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medistep Healthcare Research & Development Related Terms

Medistep Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Medistep Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistep Healthcare Research & Development Chart

Medistep Healthcare Annual Data
Trend Mar22 Mar23 Mar24 Mar25
Research & Development
0.00 0.00 0.00 0.00

Medistep Healthcare Semi-Annual Data
Mar22 Mar23 Mar24 Mar25
Research & Development 0.00 0.00 0.00 0.00
NSE:MEDISTEP
19GF Score
Medistep Healthcare Ltd NSE:MEDISTEP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medistep Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Medistep Healthcare (NSE:MEDISTEP) has a Research & Development of ₹0.0 Mil as of Mar. 2025. Research and development expense is the total cost for research and development activities. View historical data on Medistep Healthcare and its competitors.
Is Medistep Healthcare's Research & Development too high?
Medistep Healthcare's current Research & Development is ₹0.0 Mil. Overall, Medistep Healthcare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Medistep Healthcare's Research & Development compare to MCK and CAH?
Medistep Healthcare's Research & Development of ₹0.0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medistep Healthcare and its competitors. Medistep Healthcare's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistep Healthcare stock overvalued right now?
Medistep Healthcare (NSE:MEDISTEP) has a current Research & Development of ₹0.0 Mil. The current Research & Development is ₹0.0 Mil. Medistep Healthcare's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medistep Healthcare (NSE:MEDISTEP), the current Research & Development is ₹0.0 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medistep Healthcare Business Description

Address National Highway 8, 05, S. No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Near A-One Hotel, Narol Gam, Narol, Daskroi, Ahmadabad, GJ, IND, 382405
Medistep Healthcare Ltd operates in the pharmaceutical and healthcare product sectors. Its business includes manufacturing intimate care and hygiene products such as sanitary pads, as well as nutraceutical products like energy powders. The company also trades a variety of pharmaceutical, surgical, and medical equipment products. Medistep Healthcare's operations focus mainly on the western region of India, particularly in Gujarat. Its Core business activity is divided into the following categories: a) Trading of Pharmaceutical & Surgical products, b) Trading & Manufacturing of Nutraceuticals and Intimate care & hygiene products. The company generates the majority of its revenue from Trading and distribution.
19GF Score

Get the complete analysis for NSE:MEDISTEP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹19.90
Price